Personalized bleeding risk assessment for atrial fibrillation patients on direct oral anticoagulants: the DOAC score

Published: 11 October 2023
Abstract Views: 1360
PDF: 191
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Not available

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Klok FA, Huisman MV. How I assess and manage the risk of bleeding in patients treated for venous thromboembolism. Blood 2020;135:724-34. DOI: https://doi.org/10.1182/blood.2019001605
Aggarwal R, Ruff CT, Virdone S, et al. Development and validation of the DOAC score: a novel bleeding risk prediction tool for patients with atrial fibrillation on direct-acting oral anticoagulants. Circulation 2023;148:936-46. DOI: https://doi.org/10.1161/CIRCULATIONAHA.123.064556
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51. DOI: https://doi.org/10.1056/NEJMoa0905561
Kakkar AK, Mueller I, Bassand JP, et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J. 2012;163:13-9. DOI: https://doi.org/10.1016/j.ahj.2011.09.011
Carnicelli AP, Hong H, Giugliano RP, et al. Individual patient data from the pivotal randomized controlled trials of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (COMBINE AF): design and rationale from the COMBINE AF investigators. Am Heart J 2021;233:48-58. DOI: https://doi.org/10.1016/j.ahj.2020.12.002
Qazi JZ, Schnitzer ME, Côté R, et al. Predicting major bleeding among hospitalized patients using oral anticoagulants for atrial fibrillation after discharge. PLoS One 2021;16:e0246691. DOI: https://doi.org/10.1371/journal.pone.0246691
Schulman S, Kearon. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692-4. DOI: https://doi.org/10.1111/j.1538-7836.2005.01204.x
Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093-100. DOI: https://doi.org/10.1378/chest.10-0134
Borre ED, Goode A, Raitz G, et al. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review. Thromb Haemost 2018;118:2171-87. DOI: https://doi.org/10.1055/s-0038-1675400
Connolly SJ, Healey JS, Belley-Cote EP, et al. Oral Anticoagulation use and left atrial appendage occlusion in LAAOS III. Circulation 2023 Sep 21. [Epub ahead of print]. DOI: https://doi.org/10.1161/CIRCULATIONAHA.122.060315

How to Cite

Prandoni, P. (2023). Personalized bleeding risk assessment for atrial fibrillation patients on direct oral anticoagulants: the DOAC score. Bleeding, Thrombosis and Vascular Biology, 2(3). https://doi.org/10.4081/btvb.2023.97

Most read articles by the same author(s)

Similar Articles

1 2 3 4 5 6 > >> 

You may also start an advanced similarity search for this article.